This inventor holds 1 USPTO granted patent. Top assignee: Catalyst Therapeutics Pty Ltd.. Active years: 2019.
Company Filing History:
Years Active: 2019
Title: The Innovations of Jean-Marc Garnier
Introduction
Jean-Marc Garnier is a notable inventor based in Victoria, Australia. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds with therapeutic potential. His work focuses on creating innovative solutions that address critical health challenges.
Latest Patents
One of Jean-Marc Garnier's key patents is titled "Benzodiazepines as Bromodomain Inhibitors." This invention provides novel benzodiazepine derivatives of Formula I or pharmaceutically acceptable derivatives, polymorphs, salts, or prodrugs thereof. These compounds have potential as bromodomain (BRD) inhibitors, showcasing his commitment to advancing medical science.
Career Highlights
Jean-Marc Garnier is associated with Catalyst Therapeutics Pty Ltd., where he continues to push the boundaries of pharmaceutical research. His work has led to the development of innovative compounds that may significantly impact the treatment of various diseases.
Collaborations
Throughout his career, Jean-Marc has collaborated with esteemed colleagues, including Chris Burns and Phillip Patrick Sharp. These partnerships have fostered a collaborative environment that enhances the research and development process.
Conclusion
Jean-Marc Garnier's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a leading inventor. His work continues to inspire advancements in medical research and therapeutic development.